The Metagenomi Therapeutics, Inc. (Nasdaq: MGX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public biotechnology issuer focused on in vivo genome editing and precision genetic medicines. These filings offer detailed information on financial performance, pipeline progress, and key corporate events related to its proprietary gene editing toolbox and programs such as MGX-001 for hemophilia A.
Metagenomi, Inc. files current reports on Form 8-K to announce material events, including quarterly financial results, business updates, and new preclinical data. For example, Form 8-K filings reference press releases that discuss non-human primate data for MGX-001, strategic pipeline prioritization, and corporate presentations. These 8-Ks often furnish exhibits containing full press releases and investor slide decks, which can provide additional scientific and strategic context.
Investors can also review quarterly reports on Form 10-Q and other periodic filings, which the company notes in its press releases, for more comprehensive discussions of research and development activities, collaboration revenue, operating expenses, and risk factors. As an emerging growth company, Metagenomi discloses its status and related accounting elections within these documents.
On Stock Titan, MGX filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize lengthy documents such as 10-Qs and 10-Ks, highlight key sections, and clarify technical language. Users can quickly identify items related to in vivo genome editing programs, collaboration agreements, capital allocation, and organizational changes. In addition, Form 4 and other insider transaction reports, when filed, can be reviewed to monitor trading activity by directors and officers.
This page is a central resource for analyzing Metagenomi Therapeutics’ official disclosures, from financial results and pipeline data to governance updates, supporting deeper research into the MGX investment and its genome editing platform.
Metagenomi Therapeutics reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and available-for-sale marketable securities were $140.2 million as of March 31, 2026, and management anticipates this cash runway will support operations through the fourth quarter of 2027.
For the quarter, collaboration revenue was $1.25 million compared with $4.13 million a year earlier. Research and development expenses were $19.3 million versus $25.1 million, and general and administrative expenses were $6.5 million versus $6.8 million. Net loss was $23.1 million, or $0.61 per share, compared with a net loss of $25.0 million, or $0.68 per share, in the prior-year period.
The company highlighted continued progress for MGX-001, its lead hemophilia A program, which it expects to submit for regulatory review, including an IND, in the fourth quarter of 2026, with first-in-human studies planned for 2027. Metagenomi also referenced a publication in Nature Structural & Molecular Biology showcasing its compact CRISPR nuclease MG119-28 and reiterated its strategy to apply its in vivo genome editing platform to hemophilia A and additional genetic and cardiometabolic indications.
Metagenomi Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 9, 2026. Stockholders will elect two Class II directors, Juergen Eckhardt and Eric Bjerkholt, to terms running until the 2029 meeting, and ratify PricewaterhouseCoopers LLP as auditor for 2026.
The record date is April 13, 2026, when 37,647,057 common shares were outstanding, each with one vote. The company highlights a staggered three-class board, fully independent key committees, and status as an emerging growth and smaller reporting company, which allows scaled executive compensation disclosure and reduced say‑on‑pay requirements.
Metagenomi Therapeutics director and officer Jian Irish reported equity awards and updated holdings. She received a stock option covering 276,000 shares of common stock at an exercise price of $1.34 per share, expiring on March 31, 2036, with 25% vesting on April 1, 2027 and the rest in 36 monthly installments. She also received 46,000 restricted stock units, 25% of which vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments. Following these awards, she holds 379,770 shares of common stock directly, and additional shares are held indirectly by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish and the Jian Irish 2023 Irrevocable Trust, where she disclaims beneficial ownership except to the extent of her pecuniary interest.
Wein Matthew reported acquisition or exercise transactions in this Form 4 filing.
Metagenomi Therapeutics officer Matthew Wein received new equity awards. On April 1, 2026, he was granted options to buy 68,000 shares of common stock at $1.34 per share, expiring on March 31, 2036. The option vests 25% on April 1, 2027, with the rest in 36 equal monthly installments, contingent on continued service. He was also granted 11,000 restricted stock units that begin vesting 25% on June 5, 2027, then in 12 equal quarterly installments. Following these compensation-related grants, his direct common stock holdings total 125,549 shares.
Metagenomi Therapeutics Chief Financial Officer Pamela Wapnick reported new equity awards. She received a grant of 144,000 stock options with an exercise price of $1.34 per share, expiring on March 31, 2036. These options relate to 144,000 shares of common stock.
She was also granted 24,000 shares of common stock in the form of restricted stock units. Twenty-five percent of the RSUs vest on June 5, 2027, with the rest vesting in 12 equal quarterly installments. Her directly owned common stock holdings total 211,375 shares after these grants. The option award vests 25% on April 1, 2027, with the remainder vesting in 36 equal monthly installments.
Metagenomi Therapeutics, Inc. Chief Financial Officer Pamela Wapnick reported an automatic sale of common stock related to tax withholding. On this transaction date, 1,581 shares of common stock were sold at $1.60 per share. According to the footnote, the shares were automatically sold to satisfy her tax withholding obligations upon the vesting of restricted stock units granted on April 1, 2024, and the transaction did not represent a voluntary trade. After this sale, Wapnick beneficially owned 187,375 shares of common stock directly.
Metagenomi Therapeutics, Inc. officer Matthew Wein reported an automatic sale of common stock related to equity compensation. On March 5, 2026, 482 shares of common stock were sold at $1.60 per share to satisfy tax withholding obligations upon the vesting of restricted stock units granted on April 1, 2024 and April 1, 2025. The filing notes this was not a volitional trade by the reporting person. Following this transaction, Wein beneficially owned 114,549 shares of Metagenomi Therapeutics common stock.
Metagenomi Therapeutics Chief Executive Officer Jian Irish reported both a tax-related share sale and large gifts of stock. On December 5, 2025, she transferred 114,231 shares to the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish and 114,231 shares to the Jian Irish 2023 Irrevocable Trust as bona fide gifts for no consideration. These trusts now hold shares for which she disclaims beneficial ownership except for any pecuniary interest. On March 5, 2026, 1,607 shares of common stock were automatically sold at $1.60 per share to satisfy tax withholding obligations from restricted stock units that vested on April 1, 2024, leaving her with 333,770 shares held directly.